Welcome to the Stocktwits Top 25 Newsletter for Week 32 of 2022!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 32:
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+7.07%) significantly outperformed the S&P 500 index (+3.26%).
There were three major changes to the list this week.
Cardinal Health (+12.70%), Nielsen Holdings PLC (+19.70%), and Nucor Corporation (+4.57%) joined the list.
They replaced Northrop Grumman (+0.42%), Huntington Ingalls Industries (+1.27%), and Jack Henry & Associates (-1.04%).
Most notably, energy stocks rebounded after last week’s selloff.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+2.53%) performed in line the Nasdaq 100 index (+2.71%).
There were two major changes to the list this week.
Crowdstrike Holdings (+5.07%) and Paychex Inc. (+4.68%) joined the list.
They replaced Regeneron Pharmaceuticals (+2.46%) and Electronic Arts (-0.90%).
The Nasdaq 100 list generally has the least movement each week, and this week is no exception.
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+16.48%) significantly outperformed the Russell 2000 index (+4.93%).
There were five major changes to the list this week.
Cincor Pharma (+49.64%), Karuna Therapeutics (+97.65%), Catalyst Pharmaceuticals (+24.89%), International Seaways (+14.93%), and Range Resources (+10.96%) joined the list.
They replaced Tidewater Inc. (-0.72%), CVR Energy (+1.71%), Geron Corp. (-2.89%), Value Line Inc. (-4.84%), and Mirum Pharmaceuticals (-15.08%).
Several biotechnology stocks had outsized returns, despite the broader sector index pausing its advance this week.
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Karuna Therapeutics, which rallied 97.65%.
The clinical-stage biopharmaceuticals company reported earnings below expectations.
However, along with the release, it announced that its phase III EMERGENT-2 study on KarXT met its primary and key secondary endpoints. In addition, the company expects to receive topline data from the EMERGENT-3 study in Q1 2023 and to file a new drug application (NDA) with the FDA for KarXT as a treatment for schizophrenia in mid-2023.
The stock nearly doubled this week, so we guess that’s a sign investors are happy with the company’s overall progress. 🤷♂️
$KRTX is up 109.58% YTD.
See Y’all Next Week 🤙